Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blinded, placebo-controlled, investigator-initiated study of ACTEMRA (Tocilizumab) in adult onset Still's disease patients.

Trial Profile

Randomized, double-blinded, placebo-controlled, investigator-initiated study of ACTEMRA (Tocilizumab) in adult onset Still's disease patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Adult-onset Still's disease
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 New trial record
    • 24 May 2018 According to the Chugai Pharmaceutical media release, company has filed an application with the Japanese Ministry of Health, Labour and Welfare for the approval of an additional indication of adult onset Still's disease for the humanized anti-human IL-6 receptor monoclonal antibody, ACTEMRA intravenous infusion 80 mg, 200 mg, and 400 mg, based on the data from this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top